The Effect of Percutaneous Radiofrequency Ablation of Feeding Arterial for Hepatocellular Carcinoma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

120 participants

Study Classification

INTERVENTIONAL

Study Start Date

2014-05-22

Study Completion Date

2018-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

To evaluate a novel technique-ultrasound guided percutaneous abaltion of tumor feeding artery before RFA for liver malignancy.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

RFA vs. SBRT for Small HCC

NCT03898921

Hepatocellular Carcinoma

UNKNOWN PHASE3

SBRT Versus Ablation for Perivascular Hepatocellular Carcinoma

NCT04434989

Hepatocellular Carcinoma

RECRUITING NA

Standardization of Multi-modal Tumor Ablation Therapy System

NCT03223142

Liver Neoplasms Ablation Techniques Cryoablation +4 more

UNKNOWN NA

Radiofrequency Ablation Combined With Chemotherapy for Pulmonary Tumors

NCT01105182

NSCLC Pulmonary Metastases

UNKNOWN

Combined Radiotherapy and Radiofrequency Ablation for Hepatocellular Carcinoma

NCT04202523

Hepatocellular Carcinoma

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Hepatocellular carcinoma is one of the most common tumor in clinical practice. In recent years, various local therapies, especially radiofrequency ablation (RFA) has been proved safe and effective.The main limitation of RFA is that its therapeutic impact is significant compromised by blood flow cooling effect, especially in hypervascular HCC. Recent studies showed combined therapy of TACE and RFA can decrease the blood supply of tumor, increase ablated volume and therefore improve the outcome. However, TACE application is limited in patients who cannot tolerate this therapy due to the side effects of repeated TACE, poor liver function or previously legated hepatic artery. The present study is focus on "difficult-to-treat" HCC patients who are neither surgical candidates, nor TACE candidates. The investigators introduce the novel treatment mode that RFA followed ultrasound guided percutaneous ablation of tumur feeding arterial to treat these difficult cases and evaluate the clinical effect.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Liver Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

SINGLE

Participants

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

PAFA and tumor ablation

first percutaneous frequency ablation of tumor feeding artery and then ablation of tumor

Group Type EXPERIMENTAL

PAFA

Intervention Type OTHER

percutaneous ablation of tumor feeding artery

tumor ablation

Intervention Type OTHER

ablation of tumor area directly

tumor ablation

ablation of tumor directly

Group Type OTHER

tumor ablation

Intervention Type OTHER

ablation of tumor area directly

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PAFA

percutaneous ablation of tumor feeding artery

Intervention Type OTHER

tumor ablation

ablation of tumor area directly

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

percutaneous ablation of tumor feeding artery

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. tumor number ≤3， maximum tumor size ≤5cm;
2. accessibility of tumors via a percutaneous approach;
3. tumor feeding artery can be detected by 3D contrast enhance ultrasound;
4. platelet count ≥ 50,000/ml and INR \<1.6;
5. life expectancy more than 6 months
6. Child grade A or B

Exclusion Criteria

1. patients who scheduled liver transplantation
2. with extrahepatic metastasis
3. women during menstruation, pregnancy, child birth and baby nursing period
4. patients with severe mental disorder
5. cardiopulmonary failure

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No